Highlights from the 14th International Symposium on MDS

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: July 07, 2017
Expiration Date: July 07, 2018

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, leading experts in the field of MDS will share their insights and perspectives on several important and timely topics presented during scientific sessions, oral abstract presentations, and poster sessions held during the 14th International Symposium on MDS. Sessions covered include updates in molecular screening and targeting in MDS, the future role of genomics, an overview of important new and ongoing U.S. clinical trials in MDS, and the impact of aging on MDS diagnosis and treatment.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in myelodysplastic syndrome.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize key clinical trial data on novel therapies and treatment strategies in MDS
  • Recognize the potential impact of trial data on clinical practice and existing treatment paradigms

  • Identify how new advances in mutational analysis and genomics will impact diagnosis, prognosis, and treatment of MDS

Agenda

The activity includes four video sections which cover the following topic areas and abstracts:

Insights into the Mechanism of Action of Lenalidomide in Patients with Del(5q) Benjamin Ebert, MD, PhD

The Future of Genomics in MDS: What Will We Require for Our Clinical Daily Practice?Jaroslaw P. Maciejewski, MD, PhD, FACP

Aging, CHIP and MDSDavid P. Steensma, MD, FACP

Part One: Molecular Screening and Treatment in MDS, Mutant IDH as a Target, and Enasidenib

Part Two: Luspatercept in Lower Risk MDS: Updates from the PACE Study and Phase 2 Studies in Patients with Anemia – Eytan M. Stein, MD

Instructions for Participation and Credit

This activity is eligible for credit through July 07, 2018. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Benjamin Ebert, MD, PhD
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Benjamin Ebert received his medical degree from Harvard Medical School, and his doctorate from Oxford University on a Rhodes Scholarship. He completed a residency in internal medicine at Massachusetts General Hospital, and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute. Dr. Ebert is Professor of Medicine at Harvard Medical School, Boston, Massachusetts.

Dr. Ebert is president of the American Society for Clinical Investigation, an elected member of the Association of American Physicians, a member of the Broad Institute, and leader of the Leukemia Program for the Dana-Farber/Harvard Cancer Center. He serves on the medical or scientific advisory boards of the Evans Foundation, the MDS Foundation, and the Aplastic Anemia and MDS International Foundation. His awards include a Burroughs Wellcome Career Award, a Leukemia and Lymphoma Society Scholar Award, the Till and McCollough Award from the International Society of Experimental Hematopoiesis, and mentoring and teaching awards from Harvard Medical School.

The Ebert laboratory has a long-standing interest in the genetic lesions that drive myeloid malignancies, with a particular focus on myelodysplastic syndromes and clonal hematopoiesis, and the clinical and biological consequences of specific mutations. A focus of the laboratory is the mechanism of action of lenalidomide and related compounds.

Jaroslaw P. Maciejewski, MD, PhD, FACP
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Associate Director for Lerner Research Institute
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Dr. Jaroslaw Maciejewski received his medical degree and doctorate from Humboldt University Medical School, Berlin, Germany. He completed his postdoctoral fellowship at the hematology branch of the National Heart, Lung and Blood Institute, National Institutes of Health (NIH), in Bethesda Maryland. Dr. Maciejewski is Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, and Associate Director for Lerner Research Institute, Case Comprehensive Cancer Center (CCCC), at Case Western Reserve University. He is also Chairman of Translational Hematology and Oncology Research at the Taussig Cancer Institute.

Dr. Maciejewski is board certified in hematology and a diplomate in internal medicine. He holds membership in the American Society of Hematology (ASH), American Society of Clinical Investigation, American College of Physicians, the Association of American Physicians (AAP), and is chairman of the ASH Scientific Committee on Myeloid Neoplasia. Dr. Maciejewski is an editorial reviewer for Blood, Leukemia, Haematologica, Nature Genetics, Nature, Experimental Hematology, Journal of Clinical Investigation, Journal of Clinical Oncology, and The Journal of Immunology. In addition he is an editorial board member of Leukemia. He has written more than 150 peer-reviewed journal articles and book chapters. Dr. Maciejewski’s clinical areas of expertise include bone marrow failure syndromes and myeloid malignancies. His research deals with the molecular pathogenesis of these disorders and various specific aspects of stem cell biology, genetics, cytogenetics and immunobiology.

David P. Steensma, MD, FACP
Associate Professor of Medicine
Harvard Medical School
Senior Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. David Steensma received his medical degree from the University of Chicago’s Pritzker School of Medicine. He completed an internal medicine residency and a combined hematology-oncology fellowship at the Mayo Clinic in Rochester, Minnesota. He is Associate Professor of Medicine at Harvard Medical School and Senior Physician in the Division of Hematological Malignancies at Dana-Farber Cancer Institute in Boston, Massachusetts. In addition, Dr. Steensma is a consulting physician at Brigham & Women’s Hospital.

Following completion of his formal training, Dr. Steensma spent several years as a visiting research scholar in the Molecular Haematology Unit of the Weatherall Institute of Molecular Medicine, University of Oxford, England, investigating the molecular genetics of myelodysplastic syndromes. He is board certified by the American Board of Internal Medicine in internal medicine, hematology, and medical oncology. Dr. Steensma has published more than 250 peer-reviewed papers, served as editor for several American Society of Hematology (ASH) publications, is education co-chair for the ASH Annual Meeting, section editor for the Journal of Clinical Oncology, and on the hematology committee of the American Board of Internal Medicine.

Eytan M. Stein, MD
Assistant Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. He is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Stein holds board certification from the American Board of Internal Medicine, American Board of Clinical Oncology, and the American Board of Hematology. He focuses his practice on the treatment of acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. His research interests include developing novel, early phase clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-17-154-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 17-154-055

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Benjamin Ebert has received honoraria as a consultant from Grail, Inc. and H3 Biomedicine Inc. He has received grant support related to research activities from Celgene Corporation. He has also received royalties or licensing fees from Genoptix–a Novartis Company.

Dr. Jaroslaw Maciejewski has received honoraria related to speakers’ bureau activities from Alexion and Celgene Corporation, as well as consultant fees from Apellis Pharmaceuticals and Celgene. He has received grant support related to research activities from the National Institutes of Health (NIH).

Dr. David Steensma has received honoraria as a consultant from Celgene Corporation, Genoptix–a Novartis Company, H3, Incyte Corporation, and Seattle Genetics, Inc.

Dr. Eytan Stein has received honoraria related to formal advisory activities from Agios and Celgene Corporation.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of ManagingMDS.com

©2017 MediCom Worldwide, Inc. All rights reserved